When you search "Monsanto net worth," you are almost certainly looking for one of two very different things: how much the company was worth as a business, or how much the CEO made. Both are legitimate questions, but they need completely different answers, and a lot of what you will find online blurs that line in ways that make the numbers basically useless. Let me clear this up directly and give you a working framework for finding reliable figures today.
Monsanto Net Worth Explained: Company Value and CEO Wealth
Marcus Holloway
5 Apr 2026
Monsanto vs. Monsanto Company vs. the executives: what are you actually asking?
"Monsanto" can refer to a few different things depending on who is using the word and when. In the business context, Monsanto Company was an American agrochemical and agricultural biotechnology corporation publicly traded on the New York Stock Exchange under the ticker MON. It was a standalone, publicly traded company with its own balance sheet, market capitalization, and shareholder equity. That changed on June 7, 2018, when Bayer announced it had successfully completed the acquisition of Monsanto, and shares in the U.S. company would no longer be traded on the NYSE, with Bayer becoming the sole owner of Monsanto Company. So if you are researching "Monsanto net worth" and expecting to find a live stock-based valuation, you need to understand that Monsanto as an independent public entity stopped existing in mid-2018.
Sometimes people searching for Monsanto net worth are actually looking for the personal net worth of a Monsanto executive, most often the CEO. That is a separate calculation entirely, involving compensation disclosures, stock ownership, and personal equity sales rather than the corporation's balance sheet. And occasionally, people conflate "Monsanto net worth" with a general idea of how powerful or wealthy the company was, which is more of a valuation or market cap question than a strict accounting one. Getting clear on which question you are asking is step one.
Why a single net worth number for Monsanto is almost always wrong
Corporations do not have a "net worth" in the same sense that an individual does. The closest equivalent concepts are shareholder equity (assets minus liabilities as reported on the balance sheet), market capitalization (share price multiplied by shares outstanding), and enterprise value (market cap plus debt minus cash). These three figures can differ from each other by billions of dollars and all three change constantly as markets move, debt is repaid, and new shares are issued or retired.
As one concrete data point: Monsanto's Q2 2018 Form 10-Q, filed with the SEC, listed 441,283,987 shares of Monsanto common stock outstanding as of April 2, 2018. To calculate market cap at any given moment you would simply multiply that share count by the prevailing share price. But that number is not net worth. It is a snapshot of what the public markets collectively assigned as the company's equity value on a specific day. The actual acquisition price Bayer paid was approximately $63 billion, which itself reflects a premium over the pre-announcement trading price. None of these numbers are interchangeable, and none of them represent "net worth" in the household-budget sense.
Ownership structure adds another layer of complexity. Before the Bayer deal closed, Monsanto was publicly traded, meaning its "ownership" was distributed across millions of shareholders. After June 7, 2018, it became a wholly owned subsidiary of Bayer AG, a German multinational. That means there is no longer a public market price to anchor any valuation. Any figure you see quoted for "Monsanto net worth" after 2018 is either an internal Bayer accounting figure, an estimate from financial analysts, or simply outdated data being recycled. This is why you should be skeptical of any site posting a clean single number without sourcing it to a specific filing or date.
How to estimate company value using credible financial sources
For the pre-2018 period, the most reliable primary sources are Monsanto's own SEC filings: the annual Form 10-K and quarterly Form 10-Q reports. Monsanto's fiscal year 2017 Form 10-K, for example, includes a disclosed aggregate market value of the voting and non-voting common equity held by non-affiliates, computed using the share price as of the last business day of the company's most recently completed second fiscal quarter, which was February 28, 2017. That figure, pulled directly from the 10-K cover page, is one of the most authoritative single-number valuations available for that period.
Here is a practical methodology you can apply when researching any company valuation through public filings:
- Go to the SEC's EDGAR database (sec.gov/cgi-bin/browse-edgar) and search for the company's filings by name or ticker.
- Pull the most recent 10-K (annual report) filed before the acquisition. For Monsanto, that is the fiscal year 2017 10-K.
- On the 10-K cover page, find the aggregate market value of equity held by non-affiliates. This is disclosed as a regulatory requirement and is one of the cleanest valuations available.
- Cross-reference the balance sheet for shareholder equity (total assets minus total liabilities). This is the book value, which typically differs significantly from market cap.
- For post-acquisition analysis, shift your research to Bayer AG's own annual reports, which report Monsanto as a segment or subsidiary, often with goodwill and intangible asset write-downs included.
For context on how the acquisition price compares to other large agribusiness deals, it helps to look at sector-wide M&A data from financial news sources like Bloomberg, Reuters, or the Financial Times. These will give you a sense of whether a $63 billion acquisition price was a premium or discount relative to sector comparables, which in turn tells you something about how the market viewed Monsanto's fundamental value at the time of the deal.
Monsanto CEO net worth: which CEO, which timeframe?
One of the biggest pitfalls in researching executive net worth is assuming there is only one person to look up. Monsanto had multiple CEOs over its history. The most relevant for financial research purposes are Robert Shapiro (who led the company through major biotech expansions in the 1990s), Hugh Grant (who served as CEO from 2003 through 2016, overseeing much of the company's most commercially significant period), and Brett Begemann, who became CEO in 2016 and was in place when the Bayer deal was announced and closed. If you are looking for CEO net worth tied to Monsanto's peak public-market valuation and the Bayer acquisition premium, Hugh Grant and Brett Begemann are the two names most worth researching.
To estimate an executive's net worth accurately, you need to work from documented sources rather than interpolated guesses. For any Monsanto executive, the relevant public documents include proxy statements (DEF 14A filings on EDGAR), which disclose annual salary, bonus, stock awards, option awards, and other compensation in the Summary Compensation Table. Form 4 filings track open-market stock purchases and sales in real time. Schedule 13D and 13G filings capture large ownership positions. Together these tell you how much an executive was paid, how many shares they held, and when they sold equity and at what price.
It is also worth noting that exploring adjacent profiles can give useful context. For instance, Tim Mondavi's net worth illustrates how family-tied business wealth is estimated differently from salaried executive compensation, which is a useful comparison when thinking about how Monsanto leadership wealth was structured around stock grants rather than ownership stakes.
Company wealth signals vs. individual wealth signals: what the numbers actually mean
This is where a lot of readers get confused, and it is worth spending a moment here. A company's market cap, its enterprise value, and an executive's personal net worth are three completely different things, even though they are all big numbers that get cited in the same breath.
| Signal | What it measures | Where to find it | Reliability for personal net worth |
|---|---|---|---|
| Market capitalization | Total public equity value of the company | Stock exchange data, SEC 10-K cover page | Not relevant to individual wealth |
| Enterprise value | Market cap plus net debt, minus cash | Financial data providers, analyst reports | Not relevant to individual wealth |
| Shareholder equity (book value) | Assets minus liabilities on balance sheet | SEC 10-K balance sheet | Not relevant to individual wealth |
| Executive compensation | Salary, bonus, stock awards, options for the year | SEC DEF 14A proxy statement | Directly relevant, but is annual income not net worth |
| Equity holdings and sales | Shares owned and transactions executed | SEC Form 4, Schedule 13D/G filings | Most directly relevant to personal net worth estimate |
| Acquisition price | What a buyer paid to acquire the company | Press releases, SEC 8-K filings | Indirectly relevant if exec held significant shares at buyout |
The Bayer acquisition is actually a useful case study here. When Bayer paid approximately $63 billion to acquire Monsanto, executives who held vested shares or options received their pro-rata share of that acquisition price. If a CEO held, say, 500,000 shares and the buyout price was $128 per share, that position alone was worth $64 million before taxes. But that is a one-time liquidity event, not a recurring income stream, and it does not tell you anything about their other assets, liabilities, real estate, or investment portfolio. The total personal net worth figure requires aggregating all of those components, which is why reputable net worth estimates always come with ranges rather than exact numbers.
To put this in further context: even within the food and agriculture industry, executive wealth varies enormously based on how much equity they accumulated and when they chose to exercise or sell. Exploring resources like the estimated net worth of a mustard producer gives a useful lower-register comparison that shows how company size and ownership structure drive the gap between corporate revenue and individual wealth.
Where to look now and how often to re-check
Since Monsanto is no longer an independent public company, the landscape for ongoing research has shifted. Here is where to look depending on what you need:
- For historical Monsanto company financials: SEC EDGAR (search for Monsanto Company, CIK 217346). All 10-K and 10-Q filings through 2018 are archived there permanently.
- For Bayer's current reporting on the former Monsanto business: Bayer AG's Investor Relations page (investor.bayer.com), which publishes annual reports with segment-level breakdowns that often include the Crop Science division where Monsanto's assets now sit.
- For executive compensation and stock activity: SEC EDGAR DEF 14A proxy filings and Form 4 filings for the specific executives you are researching.
- For current net worth estimates of former Monsanto executives: financial biography databases, Forbes, and Bloomberg profiles updated as new information becomes available.
- For acquisition and deal context: SEC Form 8-K filings from June 2018, which include the official Bayer-Monsanto merger completion announcement.
How often should you re-check? For company-level data tied to Bayer, quarterly earnings reports come out four times a year and annual reports are typically filed in the first quarter of each calendar year. For individual executive net worth, the most meaningful updates tend to happen when new Form 4 filings show significant stock sales, when new proxy statements disclose updated compensation, or when a major financial event like an acquisition or IPO creates a liquidity event. For former Monsanto executives who may now be in different roles, checking their new employer's proxy filings is equally important.
If you are also interested in related profiles from adjacent industries or similar research puzzles, you might find it helpful to look at how estimation methodology works for entertainment figures. For example, Jonathan Moneymaker's net worth is estimated using a combination of documented earnings and equity activity, which mirrors the same approach you would apply to a corporate executive.
Your step-by-step checklist for researching this today
- Decide whether you want the company valuation or an executive's personal net worth. They require different sources and produce incomparable numbers.
- For company valuation: pull Monsanto's fiscal year 2017 Form 10-K from SEC EDGAR and note the aggregate market value of non-affiliate equity disclosed on the cover page. Cross-reference with the $63 billion Bayer acquisition price for deal-era context.
- For executive net worth: identify the specific CEO by name and the relevant timeframe (Grant for 2003-2016, Begemann for 2016-2018). Pull their DEF 14A proxy filings to get annual compensation, then Form 4s to estimate equity holdings and sales.
- Calculate a range, not a point estimate. Use the number of shares held multiplied by the acquisition price for a high-end scenario, and disclosed annual compensation compounded conservatively for a baseline.
- Check Bayer's current annual reports for ongoing crop science segment data if you need post-2018 context.
- Treat any net worth figure you find online as a starting hypothesis, not a fact. Verify it against at least one primary source before citing or acting on it.
The honest limits of any net worth estimate
Net worth figures for both companies and individuals are estimates, full stop. Even a "company net worth" drawn from a balance sheet leaves out intangible assets like brand value, pending litigation liabilities (Monsanto faced extensive litigation around its herbicide products, which Bayer has since had to settle for billions), and off-balance-sheet items. For individuals, the problem is even more acute: private real estate, family trusts, privately held investments, and debt are almost never fully disclosed in public filings.
Sites that post precise figures like "Monsanto net worth: $14.8 billion" without disclosing the date, the methodology, and the source are giving you a number that feels authoritative but may be years old or based on a single data point extrapolated beyond its usefulness. The right framing is always a range with a stated timeframe: "Based on the 2017 10-K and the Bayer acquisition price, Monsanto's equity value at the time of the deal was in the range of $55 to $65 billion." That kind of qualified statement is much more honest and actually more useful.
The same discipline applies when you encounter profiles for related figures. For instance, when you see Larry Mondello's net worth broken down on a research site, the value of that profile comes from the transparency of its sourcing and the acknowledgment of estimation uncertainty, not from the confidence with which a single number is presented. That is the standard worth applying to any net worth claim, including those about Monsanto and its leadership.
The bottom line: Monsanto's peak market cap and acquisition price put the company's equity value in the tens of billions of dollars range at its peak. Individual executives who held meaningful equity positions and participated in the Bayer buyout likely saw personal liquidity events in the tens to hundreds of millions of dollars, depending on their specific holdings and tenure. But any figure more precise than that range requires primary source verification, and any figure posted without a date and source should be treated with significant skepticism.
FAQ
If I find a “Monsanto net worth” number posted for 2020 or later, can that be correct?
It is usually not a direct, public “net worth” figure. After the 2018 Bayer closing, Monsanto stopped trading as an independent company, so any single-number claim for later years is typically an estimate, an internal accounting number, or recycled outdated data. Check whether the source ties the figure to a specific filing (or a valuation date) and whether it refers to market cap, enterprise value, equity value, or an acquisition-related mark.
What’s the quickest way to tell whether a “Monsanto net worth” article is talking about the company or the CEO?
Look for keywords like “market cap,” “enterprise value,” “share count,” or “Form 10-K/10-Q” to identify company-level valuation, and look for “DEF 14A,” “Summary Compensation Table,” “Form 4,” or “shares owned” to identify CEO or executive-level wealth. If it mixes both without separating the methodology, treat the number as unreliable.
Which figure should I use if I want the closest equivalent to “net worth” for Monsanto as a company?
Use shareholder equity for a balance-sheet concept, and market cap or enterprise value for a market-implied valuation concept. They are not interchangeable, and they move differently over time, especially around acquisitions, debt changes, and cash balances. If a site calls one of them “net worth,” verify which metric it actually means.
How do I account for the fact that acquisition price and “equity value” are not the same thing?
Acquisition price is tied to the deal structure and timing, while equity value concepts can reference different valuation dates and assumptions. For executive liquidity, the buyout price per share matters only for the portion of compensation that was vested and exercised or otherwise transferable. Any “net worth” claim that ignores structure like option treatment, vesting, and taxes is likely oversimplified.
If the CEO had stock and the deal closed, why do some net worth sites disagree on the CEO’s payout?
Because executive payout depends on specifics such as number of shares, whether awards were vested, how options were converted, sale restrictions, and tax withholding. Two estimates can start from the same deal headline but use different award counts or assume different treatment of unvested compensation, leading to materially different totals.
What mistakes should I avoid when using “share price times shares outstanding” for Monsanto?
Don’t assume the share price is constant across a period, and don’t use shares outstanding from one date with a price from another. Also distinguish “shares outstanding” from diluted share counts, and remember that market cap is a snapshot, not a lifetime value. If a source doesn’t state both the share count date and the pricing date, the calculation can be meaningless.
How can I verify the share count for Monsanto without relying on random calculators?
Pull the share count directly from Monsanto’s SEC filings for the relevant period, such as the 10-Q or 10-K cover pages, then pair it with the exact share price you are using (and the date of that price). This avoids mixing adjusted share figures with unadjusted pricing, which is a common source of wrong market cap numbers.
Are there any “hidden” liabilities I should think about when someone claims a very high corporate value?
Yes. Even when you can estimate equity value, litigation and product-related liabilities may not be fully captured as you would expect in simple headline valuations. Public numbers also may exclude certain off-balance-sheet items or future obligations, so a “company net worth” headline can omit risk that affects realistic economic value.
If I only care about executive wealth, should I rely on a single year’s compensation?
No. Executive wealth often reflects accumulated equity over multiple years, including stock grants, option exercises, and sales before and during key events. A solid approach is to combine proxy-statement compensation with Form 4 purchase and sale activity, then reconcile it with any one-time liquidity event timing.
How often should I re-check Monsanto-related valuation information today?
For company-level valuation concepts tied to the deal period, focus on the original 2018 filings and deal-date pricing, because there is no ongoing Monsanto market cap. For executive wealth, re-check when new proxy materials or new Form 4 filings appear, and when the executive changes roles, since their disclosures may shift to a new employer’s reporting context.
Why do net worth estimators often give ranges, and how should I interpret them?
Ranges reflect missing private assets and unverifiable details like personal debt, privately held investments, trust structures, and non-disclosed real estate. If an estimate presents a single precise number without showing a date and sources for the underlying equity activity, it is likely overconfident compared with the uncertainty you would expect from public filings.
